Drug Price Trends for NDC 00121-0595

Average Pharmacy Cost for 00121-0595

Drug Name	NDC	Price/Unit ($)	Unit	Date
SOD CITRATE-CITRIC ACID SOLN	00121-0595-16	0.02541	ML	2026-03-18
SOD CITRATE-CITRIC ACID SOLN	00121-0595-16	0.02514	ML	2026-02-18
SOD CITRATE-CITRIC ACID SOLN	00121-0595-16	0.02467	ML	2026-01-21

Best Wholesale Price for NDC 00121-0595

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Novo Nordisk Semaglutide Product Patent Landscape and Market Projections

Last updated: February 19, 2026

What is the patent status of Novo Nordisk's semaglutide products?

Novo Nordisk's semaglutide products, including Ozempic (for type 2 diabetes) and Wegovy (for obesity), are protected by a complex web of patents. The primary patents cover the active pharmaceutical ingredient (API) itself, its methods of use, and specific formulations.

The core patent for semaglutide is U.S. Patent No. 8,895,022, titled "Semaglutide," filed on October 19, 2012, and issued on November 25, 2014. This patent provides foundational protection for the molecule. Supplementary patents cover various aspects, such as formulations for improved stability and delivery, methods for treating obesity, and specific dosage regimens. For example, U.S. Patent No. 9,657,114, "Compositions and Methods for Treating Metabolic Disorders," issued on May 23, 2017, is relevant to its therapeutic applications.

Novo Nordisk also strategically uses "formulation patents" and "method of use patents" to extend market exclusivity beyond the expiration of the core API patent. These secondary patents can cover aspects like novel salt forms, crystalline structures, or specific pharmacokinetic profiles. The patent for the pen injector device used for subcutaneous administration is also a critical component of their intellectual property strategy.

Key patent families for semaglutide are distributed across major markets, including the United States, Europe, and Japan. Patent expiration dates vary depending on the specific patent and jurisdiction. While the core composition of matter patents are expected to expire in the mid-to-late 2030s, the expiration of formulation and method-of-use patents could be staggered. For instance, certain formulation patents might expire earlier, potentially creating windows for generic entry for specific indications or delivery methods.

The U.S. Food and Drug Administration (FDA) Orange Book lists approved drugs and their associated patent information. As of early 2024, Ozempic and Wegovy have multiple patents listed. The exact expiration dates are subject to ongoing legal challenges and potential patent term extensions.

What are the anticipated market dynamics for semaglutide?

The market for semaglutide is experiencing significant growth, driven by its efficacy in managing type 2 diabetes and, more recently, its groundbreaking success in obesity treatment. Demand has outstripped supply, leading to widespread shortages and the prioritization of Ozempic for its diabetes indication.

The obesity indication, via Wegovy, represents a substantial untapped market. While pricing for obesity treatments is a critical factor, the demonstrated effectiveness in weight loss and the potential for reducing obesity-related comorbidities are driving high patient and prescriber interest.

Key market drivers include:

• Increasing global prevalence of obesity and type 2 diabetes: These chronic conditions affect hundreds of millions worldwide, creating a vast patient population requiring effective treatments.
• Clinical trial data demonstrating significant efficacy: Semaglutide has shown robust results in HbA1c reduction for diabetes and substantial weight loss in clinical trials for obesity.
• Patient and physician preference for effective therapies: The desire for treatments that achieve significant clinical outcomes drives adoption.
• Emergence of new competitors and biosimil/generic challenges: While current patent protection is strong, the eventual expiry will lead to generic or biosimilar competition, influencing market share and pricing.

The competitive landscape is intensifying. Eli Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for obesity), a dual GIP and GLP-1 receptor agonist, has emerged as a direct competitor with similar or superior efficacy in clinical trials. Other pharmaceutical companies are actively developing next-generation GLP-1 receptor agonists and combination therapies.

The current pricing of Ozempic and Wegovy reflects their premium positioning and the significant R&D investment. For Ozempic, typical list prices are in the range of $900-$1,000 per month. Wegovy, given its weight-loss indication and higher dosage, is priced higher, often around $1,300-$1,700 per month. These prices are subject to discounts negotiated with payers and pharmacy benefit managers.

What are the price projections for semaglutide and its generics?

Projecting the price trajectory for semaglutide requires considering several factors: patent expiration, the introduction of generics/biosimil, and evolving market competition.

For branded semaglutide (Ozempic, Wegovy):

• Near-to-Medium Term (2024-2028): Prices are likely to remain strong or experience modest increases. The ongoing shortages and high demand, coupled with limited direct competition for the GLP-1 obesity indication, support premium pricing. Novo Nordisk's ability to manage supply chain constraints will be crucial.
• Long-Term (Post-Patent Expiry): Once key patents expire and generic competition emerges (anticipated mid-to-late 2030s), branded prices will face significant downward pressure. Novo Nordisk may maintain a premium for its branded products through differentiated formulations or continued lifecycle management, but broad market adoption will likely shift towards lower-cost generics.

For generic semaglutide:

• Entry Price: Upon patent expiry, generic semaglutide is projected to enter the market at a substantial discount to branded prices, potentially 50-70% lower initially. This discount is typical for generics in established therapeutic areas.
• Price Erosion: Over time, as multiple generic manufacturers enter the market, further price erosion will occur. The rate of erosion will depend on the number of approved generic versions and the market's responsiveness to lower-cost alternatives.
• Impact of Biosimil: While semaglutide is a small molecule and thus subject to generic competition rather than biosimilarity (which applies to biologics), the principle of market entry and price reduction is analogous. The concept of "biosimilar" is not applicable here, but the impact of generic competition on price is a direct parallel.

Factors influencing future pricing:

• Competitive Landscape: The success of competing drug classes (e.g., tirzepatide, oral semaglutide formulations, future incretin mimetics) will impact demand and pricing power.
• Payer Policies: Insurers and PBMs will play a significant role. Policies favoring lower-cost generics or demanding steep rebates for branded products will shape market access and pricing.
• Manufacturing Costs: The complexity of semaglutide synthesis and peptide manufacturing influences the cost base for both branded and generic producers.
• Market Penetration in Obesity: The scale of the obesity market and the willingness of healthcare systems and individuals to bear the cost of long-term obesity treatment will be a major determinant of overall market value and pricing sustainability.

The U.S. market is expected to be the largest, followed by Europe and Japan. The pricing dynamics in these regions will be influenced by national healthcare systems and regulatory pricing frameworks.

What are the regulatory and legal challenges impacting semaglutide's market exclusivity?

Novo Nordisk faces ongoing regulatory and legal challenges that could impact the exclusivity and market dynamics of its semaglutide products.

Patent Litigation: Novo Nordisk has been involved in and can expect to face further patent litigation. Competitors seeking to enter the market with generic versions will challenge existing patents. These challenges can take various forms, including Paragraph IV certifications under the Hatch-Waxman Act in the U.S., which allege that a listed patent is invalid, unenforceable, or will not be infringed by the generic product. Successful challenges can lead to earlier generic entry than anticipated.

Inter Partes Review (IPR): The U.S. Patent and Trademark Office's (USPTO) Patent Trial and Appeal Board (PTAB) offers a venue for challenging the validity of granted patents. Novo Nordisk's semaglutide patents are susceptible to IPR petitions from generic manufacturers. These proceedings can lead to the cancellation of patent claims, thus eroding market exclusivity.

Exclusivity Periods: Beyond patent protection, Novo Nordisk benefits from regulatory exclusivities granted by the FDA and other regulatory bodies. These include:

• New Chemical Entity (NCE) exclusivity: Typically 5 years in the U.S. for a new drug substance.
• Orphan Drug exclusivity: If applicable, can provide 7 years.
• Pediatric exclusivity: An additional 6 months for studies conducted in children.

These regulatory exclusivities run concurrently with patent protection but can extend the period of market protection if they expire after patents.

Off-Label Use and Label Expansion: While not directly a legal challenge to exclusivity, the widespread off-label use of Ozempic for weight loss has prompted regulatory scrutiny and highlighted the market demand for obesity treatments. Novo Nordisk has since obtained label expansion for Wegovy for obesity management, which solidifies its position but also requires robust pharmacovigilance and post-marketing surveillance.

Supply Chain Issues and Shortages: The persistent shortages of Ozempic and Wegovy have led to regulatory attention and concerns from patient advocacy groups. While not a legal challenge, it creates a less favorable environment and could influence future regulatory decisions regarding market exclusivity or generic entry timelines if sustained.

Data Exclusivity: In some jurisdictions, data exclusivity protects the clinical trial data submitted for drug approval for a certain period. This prevents generic manufacturers from relying on the innovator's data to gain approval, even if patents have expired. However, this is distinct from patent protection and has its own expiration timelines.

The interplay of patent expiration dates, successful patent challenges, and regulatory exclusivities will determine the precise timeline for generic entry and the duration of Novo Nordisk's market dominance for semaglutide.

What are the key considerations for R&D and investment decisions?

For R&D and investment decisions related to semaglutide, several critical factors require careful analysis.

R&D Considerations:

• Next-Generation Therapies: Focus on developing novel mechanisms of action or improved formulations that offer distinct advantages over current semaglutide products and competitors like tirzepatide. This could include oral formulations with improved bioavailability, combination therapies targeting multiple pathways, or drugs with enhanced safety profiles or reduced side effects.
• Obesity Market Nuances: Understand the complex pricing, reimbursement, and patient adherence challenges within the obesity market. R&D efforts should consider not only efficacy but also long-term sustainability of treatment and potential for reducing obesity-related comorbidities.
• Delivery Systems and Adherence: Innovations in drug delivery systems that improve patient convenience and adherence (e.g., longer-acting injectables, novel oral delivery) can create significant value.
• Therapeutic Area Expansion: Explore potential for semaglutide or similar molecules in other metabolic diseases or conditions where GLP-1 receptor agonism may have a beneficial effect.

Investment Considerations:

• Patent Expiration Timelines: Accurately model the impact of patent expirations on future revenue streams. Invest in companies with robust patent strategies or those poised to benefit from generic entry.
• Competitive Landscape Analysis: Continuously monitor the pipeline and market entry of competing therapies, including those from established players like Eli Lilly and emerging biotech firms.
• Payer and Reimbursement Landscape: Analyze the evolving policies of government payers (e.g., Medicare, Medicaid) and private insurers regarding GLP-1 agonists for diabetes and obesity. Reimbursement rates and formulary placement are critical for market access and revenue generation.
• Manufacturing Capacity and Supply Chain: Assess the ability of companies to meet current and future demand. Supply constraints can impact market share and investor confidence.
• Pricing Power and Sustainability: Evaluate the long-term pricing power of semaglutide, considering the impact of generics, competition, and the economic value proposition for patients and payers.
• Regulatory Pathways and Hurdles: Understand the regulatory requirements for drug approval and the potential for unforeseen delays or rejections.

The substantial market opportunity presented by semaglutide is tempered by the inherent risks associated with patent challenges, intense competition, and evolving regulatory and reimbursement landscapes. Strategic investments require a deep understanding of these dynamic factors.

Key Takeaways

• Novo Nordisk's semaglutide products (Ozempic, Wegovy) are protected by foundational composition of matter patents and secondary formulation and method-of-use patents, with core IP expiring in the mid-to-late 2030s.
• The market for semaglutide is projected to grow significantly, driven by the increasing prevalence of type 2 diabetes and obesity, and supported by strong clinical efficacy.
• List prices for Ozempic and Wegovy are substantial, ranging from approximately $900-$1,000/month and $1,300-$1,700/month, respectively.
• Upon patent expiry, generic semaglutide is anticipated to enter the market at a 50-70% discount, with further price erosion expected as competition increases.
• Novo Nordisk faces ongoing patent litigation and inter partes review challenges that could impact the timeline of market exclusivity.
• R&D and investment decisions must account for evolving competitive therapies, complex reimbursement policies, and the long-term sustainability of pricing in the obesity market.

Frequently Asked Questions

1. What is the earliest potential date for generic Ozempic or Wegovy market entry in the U.S.? While core patents are expected to expire in the mid-to-late 2030s, the earliest potential entry for a generic could be influenced by successful patent challenges or the expiration of specific formulation or method-of-use patents that are not subject to extensions. A precise date without ongoing litigation outcomes is speculative, but it is unlikely before the early-to-mid 2030s for significant market penetration.

2. How will the pricing of semaglutide likely differ between the U.S. and European markets? Pricing for semaglutide in Europe is generally expected to be lower than in the U.S. due to national healthcare systems' price negotiation powers, reference pricing, and different regulatory frameworks for drug pricing. Generic entry and subsequent price erosion may also occur on different timelines.

3. Are there any oral formulations of semaglutide that are currently approved or in late-stage development? Yes, Novo Nordisk has developed and obtained approval for Rybelsus, an oral formulation of semaglutide for type 2 diabetes. However, Rybelsus has different pharmacokinetic properties and is dosed differently than the injectable formulations.

4. What is the potential impact of Eli Lilly's tirzepatide on Novo Nordisk's semaglutide market share? Tirzepatide (Mounjaro/Zepbound) is a significant competitor. Clinical data suggests comparable or superior efficacy in both diabetes and obesity. Its market penetration will directly challenge semaglutide's dominance, particularly in the obesity segment, leading to increased competition and potentially influencing pricing strategies for both companies.

5. Beyond diabetes and obesity, are there other approved or investigated therapeutic uses for semaglutide? While diabetes and obesity are the primary approved indications, ongoing research is investigating semaglutide's potential benefits in other conditions, including cardiovascular disease reduction (as demonstrated in the SELECT trial for Wegovy), non-alcoholic steatohepatitis (NASH), chronic kidney disease, and certain neurological disorders. Approval for additional indications would expand the market and potentially extend the commercial lifecycle of semaglutide.

Citations

[1] U.S. Patent No. 8,895,022. (2014). Semaglutide. United States Patent and Trademark Office. [2] U.S. Patent No. 9,657,114. (2017). Compositions and Methods for Treating Metabolic Disorders. United States Patent and Trademark Office. [3] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). U.S. Department of Health and Human Services. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [4] ClinicalTrials.gov. (n.d.). Search for "semaglutide". National Library of Medicine. Retrieved from https://clinicaltrials.gov/ [5] Novo Nordisk. (2023). Annual Report 2023. Retrieved from https://www.novonordisk.com/ [6] Eli Lilly and Company. (2023). Annual Report 2023. Retrieved from https://www.lilly.com/